A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer

Douglas R. Vogus, Michael A. Evans, Anusha Pusuluri, Alexandra Barajas, Mengwen Zhang, Vinu Krishnan, Maksymilian Nowak, Stefano Menegatti, Matthew E. Helgeson, Todd M. Squires, Samir Mitragotri

PII: S0168-3659(17)30783-6
DOI: doi: 10.1016/j.jconrel.2017.08.016
Reference: COREL 8918

To appear in: *Journal of Controlled Release*

Received date: 20 June 2017
Revised date: 10 August 2017
Accepted date: 15 August 2017

Please cite this article as: Douglas R. Vogus, Michael A. Evans, Anusha Pusuluri, Alexandra Barajas, Mengwen Zhang, Vinu Krishnan, Maksymilian Nowak, Stefano Menegatti, Matthew E. Helgeson, Todd M. Squires, Samir Mitragotri , A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi: 10.1016/j.jconrel.2017.08.016

A Hyaluronic Acid Conjugate Engineered to Synergistically and Sequentially Deliver Gemcitabine and Doxorubicin to Treat Triple Negative Breast Cancer

Douglas R. Vogus[1], Michael A. Evans[2], Anusha Pusuluri[1], Alexandra Barajas[1], Mengwen Zhang[1], Vinu Krishnan[1], Maksymilian Nowak[1], Stefano Menegatti[2], Matthew E. Helgeson[1], Todd M Squires[1] and Samir Mitragotri[1,3,*]

[1]Department of Chemical Engineering
[2]Department of Chemistry
[3]Center for Bioengineering

University of California, Santa Barbara
Santa Barbara, CA 93106

* Send correspondence to Prof. Samir Mitragotri, School of Engineering and Applied Sciences, Harvard University, 29 Oxford St., Cambridge, MA 02138, Email: mitragotri@seas.harvard.edu